Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Rostral Dorsal Cingulum Bundle Connectivity in Patients With Bipolar Disorder

10 de novembro de 2020 atualizado por: Jennifer Sweet, MD, University Hospitals Cleveland Medical Center
The overall goal of this study is to employ diffusion-weighted imaging (DWI) and tractography to investigate differences in connectivity in the rostral dorsal cingulum bundle (CB) in patients with bipolar disorder type I (BDI) or bipolar type II (BDII) compared to matched controls, and to utilize this information to determine if high-frequency deep brain stimulation (DBS) of the rostral dorsal CB has realistic potential as a therapy for producing mood stabilization in patients with BDI or BDII.

Visão geral do estudo

Status

Concluído

Condições

Tipo de estudo

Observacional

Inscrição (Real)

45

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44106
        • University Hospitals Cleveland Medical Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Participants from all three groups will be made up of those who respond to IRB approved advertisements or are referred by a provider within the UHCMC Department of Psychiatry or other provider referral.

Descrição

  1. Inclusion and Exclusion Criteria for Group 1: Healthy Volunteers

    a. Inclusion Criteria for Group 1:

    i. Male or female, age 18 or older

    ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements

    iii. In the opinion of the investigator, has the competency to understand and sign the informed consent

    iv. Physically healthy

    v. Without any current and/or lifetime psychiatric disorder assessed with a Structured Clinical Interview for psychiatric Disorders, including the Mini International Neuropsychiatric Interview (MINI)

    b. Exclusion Criteria for Group 1:

    i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)

    ii. Progressive neurological disease such as neurodegenerative disease

    iii. Preexisting implanted electrical device (such as pacemaker or cardiac defibrillator)

    iv. Any psychiatric disorder including any severe personality disorder

    v. Currently pregnant or planning to become pregnant

    vi. Any other contraindications to the brain imaging procedures.

    vii. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription

    viii. Currently taking any steroids, stimulants, or opioid pain killers.

    ix. Currently experiencing nicotine dependence or any smoking of cigarettes or use of other nicotine containing products within a week before the imaging visit.

  2. Inclusion and Exclusion Criteria for Group 2: Medically Treatment-Responsive Bipolar Disorder

    a. Inclusion Criteria for Group 2:

    i. Male or female, age 18 or older

    ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements

    iii. In the opinion of the investigator, has the competency to understand and sign the informed consent

    iv. Meets diagnostic criteria for BDI or BDII according to the DSM-V criteria, as confirmed by a systematic clinical interview and the administration of the MINI

    v. A recent episode of depression, currently in remission with evidence-based treatments for bipolar disorder

    vi. Montgomery-Asberg Depression Rating Scale (MADRS) total score ≤ 10

    vii. Young Mania Rating Scale (YMRS, Young et al 1988) total score ≤ 8

    viii. Global Clinical Impression-Severity for Bipolar Disorder (CGI-S-BD) ≤ 2

    ix. Subject is compliant with taking medication per the investigator's discretion

    b. Exclusion Criteria for Group 2:

    i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)

    ii. Progressive neurological disease such as neurodegenerative disease

    iii. Preexisting implanted electrical device (such as pacemaker or cardiac defibrillator)

    iv. Contribution of any co-occurring psychiatric comorbidity that is disproportionate to the contribution of BDI or BDII, such as severe obsessive-compulsive disorder (OCD) or post-traumatic stress disorder (PTSD)

    v. Meets criteria for antisocial personality disorder

    vi. Meets criteria for having borderline personality disorder

    vii. There will be no exclusions based on prescribed CNS-active medications

    viii. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription

    ix. Meets DSM-V criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine and/or nicotine

    x. Currently pregnant or planning to become pregnant

    xi. Any other contraindications to the brain imaging procedures.

  3. Inclusion and Exclusion Criteria for Group 3: Treatment-Refractory Bipolar Disorder

    a. Inclusion Criteria for Group 3:

    i. Male or female, age 18 or older

    ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements

    iii. In the opinion of the investigator, has the competency to understand and sign the informed consent

    iv. Meets diagnostic criteria for BDI or BDII, currently depressed, at least moderately severe with or without psychotic features, according to the DSM-V criteria, as confirmed by a systematic clinical interview and the administration of the Structured Clinical Interview for Psychiatric Disorders, including the Mini International Neuropsychiatric Interview (MINI)

    v. Current episode lasting at least 6 months and not responding to 2 adequate evidence-based treatments for BDI or BDII assessed with the assistance of Modified Antidepressant Treatment History Form (MATHF) and verified through medical records if possible

    vi. If a subject has refused treatment with a particular FDA-approved mood stabilizer due to reasons of unacceptable side effects (such as weight gain, etc.), their wishes will be respected

    vii. Depression severity should be measured with Montgomery-Asberg Depression Rating Scale (MADRS). A MADRS total score ≥ 20 is required at Screening Visit/Baseline Evaluation.

    viii. Has experienced marked impairment as documented by a score consistent with severe impairment (7 or more on at least one of the three subscales of the Sheehan Disability Scale (SDS), which includes an assessment of work-life, family-life, and social life (no/mild impairment 0-3, moderate impairment 4-6, severe impairment 7-10)

    ix. Bipolar disorder and current depressive episode as the primary source of the patient's disability, according to both the subject and the psychiatrist

    b. Exclusion Criteria for Group 3:

    i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)

    ii. Progressive neurological disease such as neurodegenerative disease

    iii. Preexisting implanted electrical device (such as pacemaker or cardiac defibrillator)

    iv. Contribution of any co-occurring psychiatric comorbidity that disproportionate to the contribution of BDI or BDII, such as severe obsessive-compulsive disorder (OCD) or post-traumatic stress disorder (PTSD)

    v. Meets criteria for antisocial personality disorder

    vi. Meets criteria for having borderline personality disorder

    vii. There will be no exclusions based on prescribed CNS-active medications

    viii. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription

    ix. Meets DSM-V criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine and/or nicotine

    x. Active suicidal ideation with a plan or intent, a suicide attempt within past 6 months or more than 2 suicide attempts within the past 2 years

    xi. Currently pregnant or planning to become pregnant

    xii. Any other contraindications to the brain imaging procedures.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Healthy Volunteers
These participants will not have any psychiatric disorder as assessed by a structured clinical interview for psychiatric disorders.
Medically Treatment-Responsive BD
This group will be composed of participants who have BDI or BDII and have most recently been depressed but are currently in remission with evidence-based treatments for bipolar disorder
Treatment-Refractory BD
This group will be composed of participants who have BDI or BDII, are currently depressed with their current episode lasting at least 12 months and not responding to 4 adequate evidence-based treatments for BDI or BDII and who have failed, been intolerant to, or were unwilling to try electroconvulsive therapy (ECT).

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Differences in connectivity in the rostral dorsal CB in patients with BDI or or BDII compared to matched controls
Prazo: Day 1
The imaging visit will consist of an MRI with diffusion-weighted imaging (DWI) sequences
Day 1

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Jennifer A Sweet, MD, University Hospitals Cleveland Medical Center

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de janeiro de 2016

Conclusão Primária (Real)

1 de outubro de 2019

Conclusão do estudo (Real)

1 de outubro de 2019

Datas de inscrição no estudo

Enviado pela primeira vez

6 de janeiro de 2016

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de janeiro de 2016

Primeira postagem (Estimativa)

14 de janeiro de 2016

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2020

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2020

Última verificação

1 de novembro de 2020

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 02-15-35
  • KL2TR000440 (Concessão/Contrato do NIH dos EUA)

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Transtorno bipolar

Ensaios clínicos em Imagem de ressonância magnética

3
Se inscrever